CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: Homocysteine-Lowering Is Not a Primary Target for Cardiovascular Disease Prevention in Chronic Kidney Disease Patients
- 8 August 2007
- journal article
- review article
- Published by Wiley in Seminars in Dialysis
- Vol. 20 (6), 523-529
- https://doi.org/10.1111/j.1525-139x.2007.00336.x
Abstract
No abstract availableKeywords
This publication has 72 references indexed in Scilit:
- Homocysteine Hypothesis for Atherothrombotic Cardiovascular Disease: Not ValidatedJournal of the American College of Cardiology, 2006
- Homocysteine Lowering with Folic Acid and B Vitamins in Vascular DiseaseNew England Journal of Medicine, 2006
- Homocysteine Lowering and Cardiovascular Events after Acute Myocardial InfarctionNew England Journal of Medicine, 2006
- Homocysteine in uraemia--a puzzling and conflicting storyNephrology Dialysis Transplantation, 2004
- Lowering Homocysteine in Patients With Ischemic Stroke to Prevent Recurrent Stroke, Myocardial Infarction, and DeathJAMA, 2004
- Homocysteine and cardiovascular disease: evidence on causality from a meta-analysisBMJ, 2002
- Homocysteine and Risk of Ischemic Heart Disease and StrokeJAMA, 2002
- Homocysteine and arterial disease: Experimental mechanismsVascular Pharmacology, 2002
- Homocysteine and cardiovascular disease: cause or effect?The American Journal of Clinical Nutrition, 2000
- Homocysteine theory of arteriosclerosisAtherosclerosis, 1975